GNFT (GNFT) News
Follow GNFT (GNFT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
GENFIT (GNFT) Reports €95.6M Cash and Runway Beyond 2028
GENFIT reported €95.6M in cash and cash equivalents at September 30, 2026, versus €113.8M at June 30, 2026 and €101.1M at December 31, 2025. It expects existing cash to fund operations and capital expenditures beyond 202
EQUITY | Nov 05, 2026, 05:02 PM UTC
L
France's Genfit H1 revenue falls due to absence of milestone payments
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feed
EARNINGS | Sep 28, 2026, 06:02 PM UTC
L
GENFIT SA (GNFT) H1 Cash €113.8M; Net Loss €26.1M
GENFIT reported H1 2026 cash of €113.8M (vs €101.1M at 2025YE) and a net loss of €26.1M. Royalty revenue from Iqirvo rose, but no milestones were recognized in H1 2026. Management expects cash runway beyond end-2028, sub
EARNINGS | Sep 28, 2026, 05:58 PM UTC
L
GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
Lille (France), Cambridge (Massachusetts, United States); September 28, 2026 — GENFIT Euronext:GNFT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening live
EARNINGS | Sep 28, 2026, 05:58 PM UTC
L
Genfit 1H Loss/Shr EUR0.52 >GNFT.FR
Genfit 1H Loss/Shr EUR0.52 >GNFT.FR
NEWS | Sep 28, 2026, 05:54 PM UTC
L
Genfit 1H Rev EUR21.1M >GNFT.FR
Genfit 1H Rev EUR21.1M >GNFT.FR
NEWS | Sep 28, 2026, 05:52 PM UTC
L
GNFT: Commercial success in PBC, diagnostic advances in MASH, and a strong pipeline drive future growth
Strong financials and strategic partnerships support robust growth, with Iqirvo achieving significant commercial milestones and expanded market potential in PBC and PSC. Diagnostic innovation in MASH is validated by guid
NEWS | Sep 15, 2026, 03:06 PM UTC
L
GNFT NIS2+ validated as scalable non-invasive MASH diagnostics solution
TradingView News says NIS2+ has been validated as a scalable, non-invasive test aimed at unlocking the MASH diagnostic and monitoring market, supported by pharma partnerships.
EQUITY | Sep 09, 2026, 06:59 PM UTC
L
GNFT NIS2+ set to transform MASH diagnostics and patient monitoring
TradingView News says GNFT’s NIS2+ is positioned as a scalable, non-invasive solution for MASH diagnostics, validated by independent studies, aimed at enabling patient identification and monitoring.
EQUITY | Sep 09, 2026, 05:03 PM UTC
L
GNFT targets scalable non-invasive MASH diagnosis, ~$1.5B market by 2033
Genfit says a scalable, non-invasive diagnostic for at-risk MASH could unlock an annual lab market of about $1.5B by 2033. It highlights moving from LDT to IVD and expanding payer coverage.
EQUITY | Sep 09, 2026, 03:56 PM UTC
L
GNFT scalable MASH diagnostics projections point to $1.5B+ U.S. sales by 2033
A hepatology expert said there is urgent need for scalable, non-invasive MASH diagnostics. Projections cited U.S. peak sales that could exceed $1.5 billion by 2033, helped by new therapies and adoption.
EQUITY | Sep 09, 2026, 03:47 PM UTC
L
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
Lille (France), Cambridge (Massachusetts, United States), September 9, 2026 - GENFIT Euronext:GNFT, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases,
EQUITY | Sep 09, 2026, 05:37 AM UTC
L
GNFT: Robust pipeline and partnerships drive growth in rare liver diseases and diagnostics
GNFT: Robust pipeline and partnerships drive growth in rare liver diseases and diagnostics
EQUITY | Sep 01, 2026, 07:41 AM UTC